Boehringer Ingelheim and Eli Lilly announce data on diabetes portfolio

Data to be presented at the European Association for the Study of Diabetes (EASD) Annual Meeting in Vienna, Austria, will add to the extensive clinical evidence supporting the efficacy and safety profile of the diabetes portfolio from the Boehringer Ingelheim (BI) and Eli Lilly and Company (Lilly) Diabetes Alliance.

Source: Pharmacy Europe - September 10, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Diabetes clinical evidence Latest News safety profile T2D Source Type: news